ACETAMINOPHEN Drug Patent Profile

Which patents cover Acetaminophen, and when can generic versions of Acetaminophen launch?

Acetaminophen is a drug marketed by Rising, Aspiro, B Braun Medical, Baxter Hlthcare Corp, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Inforlife, Mylan, Sandoz, Wockhardt Bio Ag, Zydus Pharms, Able, Acino Prods, Perrigo New York, Taro, Aurobindo Pharma, Granules, Heritage, Marksans Pharma, Ohm Labs, Perrigo, Sun Pharm Inds Ltd, Teva, Actavis Mid Atlantic, Chartwell, Chartwell Molecular, Dava Pharms Inc, Genus Lifesciences, Pai Holdings, Pharmobedient, Strides Pharma, Am Therap, Amneal Pharms Ny, Ani Pharms, Aurolife Pharma Llc, Duramed Pharms Barr, Elite Labs Inc, Everylife, Fosun Pharma, Halsey, Hibrow Hlthcare, Kv Pharm, Lederle, Mikart, Mutual Pharm, Puracap Pharm, Purepac Pharm, Rhodes Pharms, Roxane, Specgx Llc, Strides Pharma Intl, Superpharm, Usl Pharma, Valeant Pharm Intl, Vitarine, Warner Chilcott, Watson Labs, Watson Labs Florida, Whiteworth Town Plsn, Cent Pharms, Aurobindo Pharma Ltd, Bionpharma, Dr Reddys, Glenmark Pharms Ltd, L Perrigo Co, Lnk Intl Inc, Gavis Pharms, Wraser Pharms Llc, Boca Pharma Llc, and West-ward Pharm Corp. and is included in one hundred and forty-five NDAs. There is one patent protecting this drug.

This drug has seventeen patent family members in twelve countries.

The generic ingredient in ACETAMINOPHEN is acetaminophen; caffeine; dihydrocodeine bitartrate. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetaminophen; caffeine; dihydrocodeine bitartrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Acetaminophen

Annual sales in 2022 were $10mm indicating the motivation for generic entry (peak sales were $30mm in 2005).

There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ACETAMINOPHEN

International Patents:	17
US Patents:	1
Applicants:	73
NDAs:	145
Finished Product Suppliers / Packagers:	92
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1,433
Patent Applications:	4,009
Drug Prices:	Drug price information for ACETAMINOPHEN
Drug Sales Revenues:	Drug sales revenues for ACETAMINOPHEN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACETAMINOPHEN
What excipients (inactive ingredients) are in ACETAMINOPHEN?	ACETAMINOPHEN excipients list
DailyMed Link:	ACETAMINOPHEN at DailyMed

See drug prices for ACETAMINOPHEN

See drug sales revenues for ACETAMINOPHEN

Recent Clinical Trials for ACETAMINOPHEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institutes of Health (NIH)	PHASE1
Brigham and Women's Hospital	PHASE1
AdventHealth	PHASE3

See all ACETAMINOPHEN clinical trials

Medical Subject Heading (MeSH) Categories for ACETAMINOPHEN

Analgesics, Non-Narcotic

Antipyretics

Paragraph IV (Patent) Challenges for ACETAMINOPHEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OFIRMEV	Injection	acetaminophen	650 mg/65 mL (10 mg/mL)	022450	1	2024-07-31
OFIRMEV	Injection	acetaminophen	1000 mg/100 mL (10 mg/mL)	022450	1	2011-04-07

US Patents and Regulatory Information for ACETAMINOPHEN

ACETAMINOPHEN is protected by one US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Elite Labs Inc	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen; codeine phosphate	TABLET;ORAL	212418-001	Sep 10, 2019	AA	RX	No	No
Rhodes Pharms	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen; codeine phosphate	TABLET;ORAL	089673-003	Feb 10, 1988		DISCN	No	No
Chartwell	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen; codeine phosphate	SOLUTION;ORAL	089450-001	Oct 27, 1992		DISCN	No	No
Marksans Pharma	ACETAMINOPHEN	acetaminophen	TABLET, EXTENDED RELEASE;ORAL	215486-001	Aug 25, 2021		OTC	No	No
Mikart	ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE	acetaminophen; aspirin; codeine phosphate	CAPSULE;ORAL	081095-001	Oct 26, 1990		DISCN	No	No

International Patents for ACETAMINOPHEN

See the table below for patents covering ACETAMINOPHEN around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2626068
World Intellectual Property Organization (WIPO)	2010121762
Poland	2626068
Spain	2564547
Japan	2012524738

Acetaminophen: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What drives the acetaminophen market today?

Acetaminophen (paracetamol) is a mature, high-volume analgesic and antipyretic with pricing and demand shaped by three forces: (1) broad over-the-counter (OTC) access, (2) the long safety record and entrenched substitution across pain and fever, and (3) supply-side scale from large generics manufacturers and branded-household brands.

Demand structure

• Use cases: fever and mild-to-moderate pain (headache, cold/flu symptoms, minor aches).
• Channel reality: most volume is OTC, often sold as standalone tablets/caplets and as combination products (e.g., cold and flu formulations).
• Substitution behavior: acetaminophen competes directly with ibuprofen and other analgesics in OTC shelves; in many geographies it retains share because it is perceived as easier to tolerate for certain patient groups and because it is deeply embedded in combination products.

Competitive landscape

• Generic dominance: acetaminophen is widely generic; pricing tends toward low, stable levels.
• Brand endurance: branded and “household” products persist, but their financial impact is typically limited by generic penetration and retailer private-labeling.
• Combination products: a meaningful share of revenue comes indirectly through multi-symptom products. Those formulations can support revenue resilience when single-ingredient pricing compresses.

Cost and supply dynamics

• Input and manufacturing scale: scale manufacturing favors large generic players, supporting stable supply and limiting margin expansion.
• Regulatory and labeling: acetaminophen-related safety guidance (notably liver injury risk from overdose) affects consumer dosing behavior and can influence pack sizes and marketing claims, but it does not materially disrupt the core market due to established risk-minimization practices.
• Patent status: the molecule is off-patent in major markets; product differentiation is mostly formulation, branding, and channel placement.

Demand risk factors that matter financially

• Overuse and substitution: shifts toward ibuprofen or other OTC analgesics can change mix even when overall OTC category demand stays stable.
• Seasonality: cold and flu seasons drive spikes in sales of fever reducers and combination products.
• Retail and promo cycles: price and promotion actions by major retailers can drive short-run volume swings.

How does pricing typically behave for acetaminophen?

Acetaminophen pricing is structurally constrained by generics and OTC competition. Financially, the market tends to show:

• Low unit margins relative to prescription specialty drugs.
• Revenue stability via volume and pack mix rather than unit price growth.
• Volatility tied to retailer pricing and promotional intensity, not drug-lifecycle events.

In markets with high generic penetration, price increases are usually limited to:

• packaging changes and dosing convenience,
• selective brand premium products,
• and periods of supply disruption or commodity inflation.

What is the financial trajectory implied by market structure and data?

Acetaminophen does not follow the typical “ramp to launch to peak to decline” pattern of new drugs. Its financial trajectory behaves more like a mature mass-market OTC and generics portfolio.

Trajectory pattern

• Steady baseline growth: driven by population growth and persistent OTC usage.
• Cyclicality: seasonality in respiratory season and temporary demand spikes.
• Margin pressure: recurring generic and private-label competition compresses realized pricing.
• Revenue resilience from mix: combination products and branded legacy lines can slow the rate of revenue erosion.

Practical financial read-through for investors

For companies with manufacturing exposure:

• Volume is king; capacity utilization and procurement scale dominate results.
• Pricing discipline matters; sustained price competition can suppress earnings even when volumes hold.

For brands/marketers:

• Brand and channel execution determine whether revenue holds up when generic prices reset.
• Formulation and combination mix can protect top-line growth even when standalone unit prices flatten.

What regulatory and safety dynamics shape commercialization economics?

Acetaminophen’s commercialization economics are influenced by decades of safety guidance and dosing limits. The core impact is not a major market exit risk, but ongoing operational and marketing discipline.

Safety constraint that affects product strategy

• Overdose risk management pushes manufacturers toward labeling, packaging, and consumer-dose clarity.
• Combination-product scrutiny matters because multiple-ingredient formulations can raise the risk of unintentional overdosing.
• Dose limiting affects pack formats, retailer placement strategy, and consumer messaging.

This environment supports a stable market, but it reduces the scope for aggressive product differentiation that would otherwise support higher pricing.

Where does acetaminophen financial performance concentrate: standalone vs combination?

Financially, revenue concentration is typically split between:

• Standalone acetaminophen (tablets/caplets, liquid gels in some markets).
• Combination cold and flu products, where acetaminophen is a co-active ingredient.

Because combination products are more tightly tied to seasonal respiratory demand, they can contribute to quarter-to-quarter earnings variance, with stronger performance during peak respiratory periods.

How do major company financials typically reflect acetaminophen exposure?

Public financial statements often reflect acetaminophen as part of broader:

• OTC analgesics,
• consumer health,
• respiratory symptom platforms,
• and generic manufacturing portfolios.

As a result, company-level acetaminophen “standalone” performance is usually not isolated in reporting; the molecule’s economic impact typically shows up through segment results, product-family sales, and generics volume and pricing dynamics.

What do market dynamics imply for future financial outcomes?

Near-to-medium-term, the acetaminophen market is likely to remain:

• volume-led with modest topline growth,
• price-pressured due to generic competition,
• mix-shifting toward convenience and combination products in many markets.

Key drivers likely to steer financial outcomes include:

• retailer promotional strategy,
• changes in private-label share,
• seasonal severity (respiratory season),
• and competitive intensity among large generic manufacturers.

Outlook by scenario (directional)

• Base case: stable demand, modest revenue growth from volume and mix, limited margin expansion.
• Downside: increased promotional intensity and further private-label capture reduce realized pricing faster than volumes can offset.
• Upside: stronger-than-average respiratory seasons and better combo-product mix improve revenue per unit sold, with some mitigation of margin compression.

How should R&D and portfolio decisions be evaluated for acetaminophen?

Given the mature status of the molecule, R&D value tends to concentrate in:

• reformulation (improved onset, palatability, dosing convenience),
• combination optimization (dose clarity and adherence design),
• and manufacturing/process improvements for cost-of-goods advantage.

For portfolio strategy:

• The highest financial upside typically comes from operational excellence and channel execution rather than new clinical differentiation, because the molecule’s clinical baseline is already well-established.

---

Key Takeaways

• Acetaminophen is a mature, high-volume OTC and generics market where financial outcomes are driven by volume, mix (standalone vs combination), and realized pricing, not drug-lifecycle events.
• Generic and private-label competition caps sustained price increases, so revenue resilience comes from combination products, convenience formats, and seasonal demand.
• Safety and labeling guidance constrain some differentiation but do not structurally disrupt market access; commercialization remains stable with ongoing risk-minimization practices.
• Future financial trajectory is likely steady topline with margin pressure, unless a producer wins through channel execution and cost leadership.

FAQs

1. Is acetaminophen growth expected to be driven by prescription adoption?
   No. The core economics are OTC-driven with limited reliance on new prescription-driven demand.

2. What most affects acetaminophen quarterly financials?
   Seasonality tied to respiratory illness demand and retailer promo intensity, especially for combination cold and flu products.

3. Why does acetaminophen pricing rarely sustain long-term increases?
   Extensive generic supply and private-label competition reset realized prices toward low, stable levels.

4. What product mix changes matter most commercially?
   The mix between standalone acetaminophen and combination symptom products, plus convenience formats that can support incremental revenue per unit.

5. Where can financial upside still be created in acetaminophen?
   Manufacturing cost leadership, distribution and retailer execution, and winning formulation or combination placement within OTC shelves.

---

References

[1] US Food and Drug Administration. “Acetaminophen: Safety and Dosing Information.” FDA. https://www.fda.gov/ (accessed via FDA acetaminophen safety pages).
[2] World Health Organization. “Paracetamol (acetaminophen).” WHO. https://www.who.int/ (accessed via WHO paracetamol resources).
[3] NHS. “Paracetamol.” National Health Service. https://www.nhs.uk/ (accessed via NHS guidance pages).

DrugChatter Q&A for ACETAMINOPHEN

What precautions should be taken when combining acetaminophen and lipitor?
How often can i take acetaminophen while on lipitor?
What about acetaminophen and lipitor interactions?
Are there alternative pain relievers to acetaminophen for those taking lipitor?
What about acetaminophen and lipitor?